Loading...
Loading...
SCPH| Name | Value |
|---|---|
| Revenues | 10.0M |
| Cost of Revenue | 3.3M |
| Gross Profit | 6.7M |
| Operating Expense | 24.9M |
| Operating I/L | -18.1M |
| Other Income/Expense | -17.0M |
| Interest Income | 0.9M |
| Pretax | -35.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -35.1M |
scPharmaceuticals Inc. is a pharmaceutical company specializing in the development and commercialization of innovative pharmaceutical products. Its lead product candidate, FUROSCIX, is a formulation of furosemide delivered through an on-body infusor for treating congestion in heart failure patients. The company's product pipeline also includes scCeftriaxone, an antibiotic for treating infections caused by gram-positive and gram-negative organisms, and the scCarbapenem program for treating infections caused by gram-negative organisms. Additionally, scPharmaceuticals Inc. has a development agreement with West Pharmaceutical Services, Inc. for the creation of a single-use SmartDose device.
